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Summary 
The major target organ for hepatitis B virus (HBV) is the liver. However, cells other than hepatocytes, 
including peripheral blood lymphocytes and monocytes, may become infected with HBV. The 
cell receptor binding site was assigned to the preS(21-47)  segment of the HBV envelope protein. 
HBV receptors were detected on human liver and hepatoma cells, on B lymphocytes, and, as 
shown here, on monocytes, and T cell lines,  activated by Escherichia  coli lipopolysaccharide and 
concanavalin A, respectively. The cell receptors for HBV have not been characterized until now. 
The detection of HBV receptors and their "activation antigen" characteristic on distinct cells 
suggested paths for identification of the receptors with already defined cell surface proteins. This 
search revealed that interleukin 6 contains recognition sites for the preS(21-47)  sequence and 
mediates HBV-cell  interactions. Thus,  HBV belongs to a group of viruses utilizing cytokines 
or cytokine receptors for replication and interference with the host immune system. 
H 
epatitis  B  virus (HBV), 1 a member of the family of 
hepadnaviridae (1), is a major human pathogen impli- 
cated in primary hepatocarcinoma. Its major target organ is 
the liver but cells other than hepatocytes, including PBL, may 
become infected (2). The HBV envelope (env) consists of three 
distinct related proteins, designated S, M, and L protein, which 
are products  of a  single env  gene.  These proteins  share a 
common 226 COOH-terminal amino acid sequence (S pro- 
tein). M  protein has an additional 55 amino acid sequence 
located at  the NH2  terminus (preS2  sequence). L  protein 
differs from M  protein by an additional NH2-terminal 108 
or 119 amino acid sequence designated as preS1. The site medi- 
ating the attachment of HBV to human hepatoma HepG2 
cells (3-5) and to human liver plasma membranes (6, 7) en- 
compasses amino acid residues (21-47) of the preS1 sequence. 
The presence of receptors for the preS (21-47)  region of 
the HBV env protein was demonstrated also on cells of non- 
hepatic origin, including PBL, hematopoietic cell lines of the 
B cell lineage, and some carcinoma and simian virus 40 (SV- 
40)-transformed cell lines (2). HBV DNA or RNA was de- 
tected not only in B lymphocytes but also in T lymphocytes 
(8)  and in PBMC  (9) of HBV-infected humans and chim- 
panzees. However, preSl-specific cell receptors for HBV were 
not detected on T cells, PBMC, or promonocytic cell lines 
1  Abbreviations used in this paper: HBsAg, hepatitis B surface antigen; HBV, 
hepatitis B virus; PI-PLC, phosphatidylinositol-specific  phospholipase C; 
SV-40, simian virus 40. 
(2; see below). To resolve this apparent discrepancy, we searched 
for the expression of HBV receptors in cell lines of the latter 
two lineages after activation with lectins and LPS,  respec- 
tively.  The emergence of HBV  receptors could indeed be 
demonstrated after activation of the cells. The constitutive 
expression of HBV receptors in several cell lines and their 
induced expression in the additional lines facilitated the de- 
sign of strategies to define the receptors. The quest to char- 
acterize preSl-specific receptors for HBV led to the identifica- 
tion of II:6 as a cell attachment site for HBV.  Thus, HBV 
appears to belong to a group of viruses utilizing interactions 
between vitally encoded proteins and cytokines or cytokine 
receptors as steps  in replication (10-16). 
Materials and Methods 
Attachment of  Cells to Immobilized Ligands.  The following human 
cells and cell lines were used: PBL isolated as described (2); purified 
PBMC (Advanced  Biotechnologies, Inc., Columbia, MD); HepG2 
hepatoma cells; Cates 1B (embryonic carcinoma); Wish (amnion); 
SK-N-SH (neuroblastoma); U937; RPMI 8226 and U266 (my- 
eloma); Namalwa and Cess (B lymphoblast); MOLT-3, MOLT-4, 
CEM, Jurkat, HUT 78, Hg, MT-4 (all seven  T cell leukemia lines); 
FS-4 (foreskin); and COS-1 (SV-40-transformed African Green 
monkey kidney cells). The cells were obtained from the American 
Type Culture Collection (ATCC; KockviUe, MD) or from donors 
listed in Acknowledgments. The cells were propagated as described 
before (2, 3) or as recommended by ATCC. For ligand binding 
studies, the cells were used either untreated, treated for 5 rain at 
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phospholipase C (PI-PLC; 1 U/ml for 1 h at 37~  in 0.14 M NaC1, 
0.01 M Tris, 0.02% NAN3, pH 7.2 [TS]). PI-PLC was a gift from 
Dr. M. G. Low (Columbia University, New York, NY) or was 
purchased from Boehringer Mannheim Biochemicals  (Indianapolis, 
IN). These treatments did not affect cell viability as determined 
by trypan blue exclusion tests. 
Selected  T cell lines, PBMC, and the promonocytic cell line U937 
were stimulated by adding to the appropriate tissue culture media 
Con A (50 ~g/ml; Sigma Chemical Co., St. Louis, MO) and Esch- 
erickia coli LPS (5/~g/ml; catalog no. 055:B5; Sigma Chemical Co.), 
respectively, for time periods indicated in Results. 
PreS(12-47)- and preS(12-32)-cellulose  and cellulose with cova- 
lently linked serum-derived hepatitis B surface antigen (HBsAg) 
containing the preS1 sequence were all prepared as described be- 
fore (2, 3). Magnetic beads with attached mAb to CD antigens 
and cytokine receptors, respectively,  were prepared as follows. Mag- 
netic beads with covalently  attached goat anti-mouse IgG and IgM 
and anti-rat IgG, respectively (depending on the mAb used) (300 
/~1; Advanced Magnetics, Inc., Cambridge, MA), were mixed with 
50/~g of the respective mAb overnight at 4~  Unadsorbed anti- 
bodies were removed,  the beads were washed four times with 0.14 M 
NaC1, 0.01 M phosphate, 0.02% NAN3, pH 7 (PBS), and resus- 
pended in 300 #1 of TS. mAb to CD antigens were obtained from 
Amac, Inc. (Westbrook, ME) or from donors listed in Acknowledg- 
ments. Antibodies to IL-2R/3 chain were obtained from Endogen 
(Boston, MA). Monoclonal and polyclonal  rabbit antibodies to Ib6 
were obtained from Genzyme (Cambridge, MA). The rabbit anti- 
IL-6 corresponded to an IgG prepared from serum by ammonium 
sulfate precipitation. 1 mg of the partially purified IgG was reported 
by the manufacturer to neutralize 100 ng of Ib6 after prolonged 
incubation. 
The attachment of cells to the cellulose derivative was quanti- 
rated as described before (2, 3). The SD of  relative cell counts, each 
based on 14 OD determinations, was g  +  8% (2). To detect the 
attachment of cells to mAb-coated magnetic beads, 50/~1 of beads 
('~5  x  10  s particles/ml) was mixed with 5  x  10  s cells in 0.5 ml 
of TS containing  1 mM CaC12 and 10 mg/ml of BSA (TS-Ca- 
BSA). After mixing for 30 rain at 20~  attached and unattached 
cells were separated magnetically and quantitated by measuring lac- 
tate dehydrogenase activity as described before (2, 3). 
The inhibitory effect of mAbs, of polyclonal rabbit antiserum 
to partially purified HBV "receptor" (final dilution, 1:5; references 
2 and 3), and of distinct cytokines on the interaction between cells 
and the respective immobilized ligands was followed by adding the 
respective  substances to the ceU-ligand  mixtures otherwise following 
conditions to study the attachment  of cells to the respective im- 
mobilized ligands. The final concentrations of the respective in- 
hibitors are presented in Results. In addition to antisera and mAbs, 
the following cytokines were studied for inhibitory activity: IL-3 
and IL-6 produced in CHO cells (both from Genetics Institute, 
Cambridge, MA); Ib7 (Sterling Drug, Inc., Malvern, PA); IL-5 
(from E. coli), leukemic inhibitory factor, and TGF-cx  and "B (all 
four from Amgen, Thousand Oaks, California). CHO cell- and 
yeast-derived I1.,6 was also obtained from Genzyme, and E. coli- 
derived Ib6 from tk & D  Systems (Minneapolis, MN). 
Measurement of Association between IL.6 and the preS1 Region of 
the HBV env Protein.  The association between IL-6 and the pep- 
tide preS(21-47) was measured by affinity chromatography. PreS(21- 
47)-cellulose (1.6 mg of the cellulose derivative in a final volume 
of 100/zl TS-Ca-BSA) was mixed with 500 ng of IL-6. After incu- 
bation for 1 h at 20~  the cellulose  derivative was pelleted by cen- 
trifugation,  transferred to a minicolumn,  and eluted with 4 M 
MgC12 at 20~  II.-6 was determined in the original preparation 
and the wash and eluate by ELISA after diluting  the specimens 
1,000-fold. The ELISA kit to quantify Ib6 (Intertest 6X) was ob- 
tained from Genzyme. The kit uses yeast Ib6 as a calibration stan- 
dard and detects IL-6 from mammalian cells with a lower senti- 
tivity (•1/15)  as compared with E. coli or yeast Ib6 (own data). 
Control experiments were carried out with preS(12-32)-ceUulose. 
The respective cellulose derivatives  contained 5-10 mg of peptides 
per gram of cellulose. 
The formation  of complexes between  HBsAg containing  the 
preS1 sequence  and Ib6 was detected  by a sandwich ELISA  utilizing 
wells coated with anti-preS1 mAb F35.25 (1/~g per well; reference 
5) or with goat antibodies to S protein (obtained as part of  an ELISA 
kit from Nuclear Medical Laboratories,  Irving, TX), and biotinyated 
polyclonal rabbit anti-IL-6. Graded quantities of distinct HBsAg 
preparations were incubated with II.-6 in the diluent used for the 
Intertest 6X kit for 30 min at 25~  followed by 90 min at 4~ 
Subsequently, the mixtures were transferred to wells coated with 
the respective (anti-S or anti-preS1) antibodies. After overnight in- 
cubation, the quantity of attached Ib-6 was determined using re- 
agents from the Intertest  6X kit. The following preparations of 
HBsAg were utilized in these tests: L protein produced in yeast 
(18); recombinant HBsAg (produced in CHO cells) either lacking 
(19) or expressing  the preS1 sequence  (',~  10 ng of the preS1 sequence 
per/~g of HBsAg; Bio-Technology  General, Rehovot, Israel); serum- 
derived HBsAg (containing 50 ng of the preS1 sequence per/~g 
of HBsAg; reference 3), and recombinant HBsAg consisting of S 
protein produced in yeast (20). 
Ultrafiltration was used to demonstrate directly the association 
between HBsAg and IL-6 and to determine the equilibrium be- 
tween bound and unbound II.-6. Distinct  quantities of HBsAg 
preparations and of recombinant L protein listed above (10 ng to 
I l~g) were mixed with I1_,6 (5-89 ng in 1 ml of TS-Ca containing 
1 mg/ml of BSA and 0.25 mg/ml of gelatine prefiltered through 
a 0.22-# filter). After incubation for 2 h at 20~  the mixtures 
were transferred into Ultrafree-CL filters (Millipore, Bedford, MA) 
and centrifuged at 2,000 revolutions/min.  The filtrates were as- 
sayed for IL-6 by ELISA after appropriate dilution. Based on pre- 
liminary experiments, filters with a cut-off of 3  x  102 kD were 
selected, since unbound Ib6 was not retained by these filters, while 
both HBsAg and L protein, existing predominantly in the form 
of aggregates (18), were retained by the ultrafiltration membranes 
of this porosity. The experiments were carried out with rlL-6 pro- 
duced in CHO cells (Genetics Institute).  Similar results were ob- 
tained with Ib6 produced in yeast and E. coli, respectively. 
Results 
Induction  of HBV Receptors in Cells That Do Not Constitu- 
tively Express the Receptors.  HBV DNA and ILNA were de- 
tected in peripheral B cells,  T  calls,  and monocytes (8,  9). 
On the other hand, HBV receptors were detected only on 
cells belonging to the B cell lineage (2). To resolve this ap- 
parent discrepancy, we wished to determine whether or not 
the expression of HBV receptors can be induced in T  cell 
lines. HUT-78 and MOLT-3 cells stimulated with Con A at- 
tached to a peptide from the preS1 sequence of the HBV env 
protein (preS[21-47])  covalently attached to cellulose, indi- 
cating the presence of HBV receptors on these cells (Fig.  1). 
Expression of the receptors appeared to be maximal after ac- 
tivation for 24 h and gradually declined after prolonged in- 
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Figure 1.  Effect of preactivation  by Con A (50 #g/m1) of distinct T 
cell lines on their attachment  to preS(21-47)-cellulose. The time interval 
for stimulation  in days is indicated  on top of the bars. Results  obtained 
with unstimulated  cell lines are shown in the first (front) row. 
cubation with Con A. HUT-78 and MOLT-3 cells not ex- 
posed to Con A failed to attach to the cellulose derivative, 
indicating the absence of HBV receptors on nonstimulated 
cells. On the other hand, H9 cells, related to the prototype 
HUT-78 cell line (21), expressed HBV receptors constitutively. 
The expression of HBV receptors was also induced by Con A 
in Jurkat cells (66% attachment to preS[21-47]-celIulose) but 
not in the T  cell lines CEM,  MOLT-4, and MT-4 (<10% 
attachment; data not shown). Cells that attached to preS(21- 
47)-cellulose also attached to HBsAg containing the preS1 
sequence covalently linked to cellulose (HBs-cellulose).  How- 
ever, they did not attach to another peptide from the preS1 
sequence, preS(12-32) linked to cellulose. Attempts to induce 
the expression of HBV receptors on the majority of T cells 
from PBL by Con A were unsuccessful (data not shown). 
Results of experiments to be described later indicated that 
recognition sites for the HBV env protein were also induc- 
ible by LPS in PBMC and a promonocytic cell line, U937 
(see Fig.  8). 
Treatment of Cells with PI-PLC Diminishes the Surface Ex- 
posure of Recognition Sites for the HBV env preS(21-47) Se- 
quence.  A subset of cell surface proteins are anchored to the 
membrane by covalent linkage to an oligosaccharide which 
is glycosidicaUy linked to PI. They can be released from cells 
by PI-PI.C (22, 23). Several leucocyte cell differentiation (CD) 
antigens, including activation antigens, are PI anchored (24). 
Since HBV receptors are expressed or inducible on several 
lineages of hemopoietic ceils in addition to hepatoma and 
liver cells, it was of interest to determine whether or not treat- 
ment with PI-PLC renders these cells nonreactive with the 
preS(21-47)  ligand. Susceptibility to cleavage by PI-PLC, if 
demonstrable, was expected to facilitate the characterization 
of HBV receptors and their possible  identification with al- 
ready characterized cell surface proteins. The percentage of 
HepG2 cells attaching to (21-47)- or HBs-cellulose decreased 
to background levels after treatment with PI-PLC (Fig.  2). 
Receptors for HBV became gradually reexpressed on the treated 
cells after subsequent cultivation in tissue culture media. Treat- 
ment with PI-PLC resulted in decreased attachment to preS1 
ligands of most other cell lines tested. However, RPMI 8226 
myeloma cells, H9, and Con A-activated MOLT-3 and HUT- 
78 T  cell lines treated with PI-PLC continued to adsorb to 
the cellulose derivatives.  A cell-specific heterogeneity in sen- 
sitivity of PI-anchored membrane antigens to release by PI- 
PLC was noted before (23) and may explain the observed ex- 
ceptions. A decrease in the ability of PI-PLC to remove PI- 
anchored surface proteins from activated T  cells was also 
reported (25). These results suggest that similar binding sites 
for the preS1 region of the HBV env protein are attached 
to the cell membranes of most, if not all cells tested, through 
a PI anchor. 
Expression of  Leukocyte Differentiation CD Antigens on HepG2 
Cells and Their Distinctiveness  from Binding Sites  for HBV.  Since 
preSl-specific receptors for HBV, first detected on human hepa- 
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Figure  2.  Effect of treatment with 
PI-PI.C  (1  U/ml,  1  h  at  37~  of 
distinct  cell lines on their attachment 
to  HBsAg-cellulose  and  preS(21-47)- 
cellulose, respectively. The attachment 
of untreated  cells to the cellulose de- 
rivatives is shown in the first (front) row; 
the attachment  of cells treated with PI- 
PI.C is shown in the second row. Treated 
HepG2 cells were washed to remove PI- 
PI.C and subsequently grown in tissue 
culture  media  (see Materials  and 
Methods)  for time intervals indicated 
on  top of the bars. The attachment 
of these cells to HBsAg-celluiose  was 
then determined  (rows 3-6). HUT 78 
Con Ald and MOLT 3 Con A 3d are 
designations  for  the  respective  cell 
lines treated I and 3 d, respectively,  with 
Con A. 
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on PBL B cells and on activated T cell lines and PBMC,  it 
seemed possible that a CD antigen might also function as 
an HBV receptor. This possibility appeared attractive, since 
some CD antigens were identified as receptors for other viruses 
(CD4, CD21, and CD54; 26-29). Therefore, the expression 
of CD antigens on HepG2 cells was studied. Because of the 
expression of HBV  receptors  on  several hemopoietic cell 
lineages, the studies were limited to those CD antigens that 
are not considered specific markers to distinguish  one cell 
lineage from another. Platelets and RBCs did not react with 
preS1 ligands. Therefore, CD antigens expressed on the latter 
two cell types were not searched  for their expression on HepG2 
cells. Among the 33 CD antigens searched for, only five ap- 
peared to be expressed on the surface of HepG2 cells abun- 
dantly enough to mediate the attachment of these cells to 
magnetic beads coated with the respective anti-CD mAbs 
(Fig. 3). These antigens were: CD58 (LFA-3), CD59, CD69, 
CD71 (transferrin receptor), and CD73 (ecto-5'-nucleotidase). 
Three of these antigens (CD58, CD59, and CD73) are linked 
to the cell membrane by a PI anchor and two antigens (CD69 
and CD71) are defined as activation markers (24). Another 
activation antigen, 4F2 (30), was also present on the surface 
of HepG2 cells. 
After establishing the surface expression of several  CD an- 
tigens on HepG2 cells, experiments were carried out to de- 
termine whether or not any of these antigens recognized the 
preS(21-47) site on the HBV env protein. First, it was deter- 
mined whether or not any of the mAbs directed against each 
of the six antigens referred to above would inhibit the at- 
tachment of HepG2 cells to preS(21-47)- and HBs-cellulose, 
respectively. Second, the effect of  polyclonal rabbit antibodies 
to the HBV receptor (3) on the attachment of HepG2 cells 
to magnetic beads coated with mAbs against the respective 
CD antigens and 4F2 was investigated. In no case were there 
any inhibitory effects observed, suggesting that none of these 
CD/activation antigens functioned as receptors for the preS1 
region of the HBV env protein. 
Inhibitory Effect of  lL6 on the Attachment of Cells Expressing 
the HBV Receptor to (21-47)- and HBs-Cellulose.  After exclud- 
ing all CD antigens tested as candidate HBV receptors, the 
possibility was considered that cytokine receptors might be 
involved in  the interaction  between the preS1 region of 
the HBV env protein and cells. To address this possibility, 
the inhibitory effect of several cytokines on the reaction be- 
tween HepG2 cells and preSl-specific ligands was examined. 
In complementary experiments, the expression of some cy- 
tokine receptors  on HepG2 cells  was assayed  using experimental 
procedures analogous to those for detection of the expres- 
sion of CD antigens  (Fig. 3). 
I1.3, IL-5, 11-7, TGF-ot and -~, and leukemic inhibitory 
factor, all at concentrations  of 5-20/zg/ml, did not inhibit 
the attachment of HepG2 cells to preS(21-47) cellulose. The 
IL-2R c~ chain (CD 25; Fig. 3) and II.-2R ~ chain (data not 
shown) were not detectable on HepG2 cells. On the other 
hand, I1.6Rs were expressed on HepG2 cells, as detected by 
both cytofluorometry  and by attachment of these cells to anti- 
I1.6tL-coated beads (data not shown), in agreement with al- 
ready published data (31). The inhibitory effect of I1.-6 on 
the interaction between HepG2 cells and preS(21-47)-cellulose 
was investigated originally to determine whether or not I1.6R 
blockade would interfere with cell attachment. Results shown 
in Fig. 4 indicate that I1.6 indeed inhibited the attachment 
of HepG2 cells to preS(21-47)-cellulose in a dose-dependent 
fashion.  This inhibitory effect was abrogated  by anti-IL-6 
mAbs. The attachment of HepG2 cells to HBsAg-cellulose 
was also inhibited by Ib6 at similar concentrations (data not 
shown). The interaction of other selected cell lines with the 
preSl-specific ligand was also inhibited (Fig. 4). 
11.,6 and Not IL,6R Carries the Binding Site for the preS(21-47) 
Segment of the HBV env Protein.  The inhibition of attach- 
ment of HepG2 ceils to preS(21-47)- and HBs-cellulose by 
IL-6 suggested the possibility the IL-6R carried sites directly 
involved in attachment of HBV. However, this notion is in- 
compatible with the following findings. (a) The inhibitory 
effect of I1.6 occurred at concentrations  that are by several 
orders of magnitude higher than physiological  concentrations. 
(b) Since the number of IL-6R sites per cell for different cell 
types is <2  x  104 (31, 32), and the Kd for the I1.6/I1-6R 
reaction is between 100 and 700 pM, the concentration of 
Ib6 required to prevent attachment of HepG2 and of other 
cells to preS(21-47)- or HBs-cellulose (>20 nM) by far ex- 
ceeded the concentration of IL-6 required for occupancy of 
cellular I1.6R sites. (c) Ceils reported to have IL-6R, for ex- 
4F2 
COTI  CD73 
ioo. 
,5 
7,5- 
CD69 
50- 
U 
Figure 3.  Occurrence  of leucocyte CD an- 
tigens on HepG2 cells as determined from their 
attachment  to magnetic beads with covalently 
linked  anti-mouse IgG, subsequently  coated 
with mAb to distinct  CD antigens.  Hatched 
columns  correspond  to  activation  antigens. 
HepG2 cells also did not attach  to magnetic 
beads coated with mAb to CD14, CD28, and 
CD39,  respectively. 
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Figure 4.  Inhibition by IL-6 of attachment 
of distinct cell lines to preS(21-47)-cellulose. 
IL-6 produced in CHO cells (CHO IL6; 12.5 
/~g; from Genetics Institute) was added to sus- 
pensions  of different cell lines before mixing 
them with preS(21-47) celhlose. The inhibi- 
tory effect of CHO Ib6 (from Genzyme), at 
distinct levels, indicated on top of the bars was 
studied using HepG2 cells. The inhibitory  effect 
of CHO IL-6 (2.5/~g) was abrogated by anti- 
Ib6 mAb (500/~g) but not by normal isotype- 
matched IgG. 
ample, CESS, HL-60, unstimulated U937 promonocytic cells, 
and peripheral T  cells (32,  33),  do not express detectable 
binding sites for the preS1 region of the HBV env protein 
(3; data not shown). (d) The attachment of HepG2 cells to 
magnetic beads coated with anti-IL-6R mAbs was not in- 
hibited by antibodies to the HBV receptor generated as de- 
scribed before (3), indicating the distinctiveness of IL-6R and 
receptors for HBV. Therefore, explanations other than the 
direct involvement of ILo6R in the binding of HBV had to 
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Figure S.  Attachment of II.-6 to preS(21-47)-cellulose.  IL-6 (500 ng) 
was added to preS(21-47) cellulose and control, preS(12-32)-ceUulose (1.6 
mg of each cdlulose derivative in a final volume of 100 #1), each suspended 
in 0.14 M NaC1, 0.01 M "Iris, 0.02% NAN3, 1 mM CaC12, pH 7.2 (TS- 
CA), containing 10 mg/ml BSA. After incubation for 1 h at 4~  and 
centrifugation, the supernatants were removed,  the cellulose derivatives 
were washed with TS-CA, and subsequently eluted at 20~  with 4 M 
MgC12. IL-6 was determined by ELISA in the supernatants  and eluates, 
and the percentages  of recovered IL-6 in these fractions were determined 
(numbers on top of the bars). 
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be established to understand the inhibitory effect of IL-6 on 
the interaction between cells and preSl-specific  ligands. 
Further experiments were designed to determine whether 
or not Ib6 reacted with the preS1 ligand and thereby inhibited 
the interaction between ceils and preS(21-47)- or HBs-cellulose. 
First, Ib6 was chromatographed on a minicolumn  of preS(21- 
47)-cellulose. Most (92.9%) of the IL-6 adsorbed to the cel- 
lulose derivative and was subsequently eluted (49%) by 4 M 
MgC12 (Fig. 5). When similar experiments were carried out 
with preS(12-32)-cellulose,  previously shown not to attach 
any of the cell lines reacting with the preS1 ligand (2, 3), 
most of the IL-6 remained unabsorbed. To confirm that at- 
tachment of Ib6 to preSl-specific cellulose derivatives indeed 
prevented their subsequent interaction with cells expressing 
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Figure 6.  HBsAg-mediated attachment of Ib6 to wells of polystyrene 
plates coated with anti-preS1 F35.25. The following preparation of HBsAg 
were used: serum-derived HBsAg containing S, M, and L protein; rHBsAg 
produced in CHO cells and either consisting of S, M, and L protein (CHO 
S-M-L rHBsAg) or of S and M protein only (CHO S-M HBsAg; 19); 
rHBsAg produced in yeast consisting of S protein (S rHBsAg; 20); and 
L protein produced in yeast (18). the HBV receptor, preS(21-47)- and HBs-cellulose (40 mg 
each) were premixed with I1.-6 (10 #g), washed with 0.14 M 
NaC1, I mM CaC12 containing 10 mg/ml of BSA (TS-Ca- 
BSA), and their ability to attach HepG2 cells was tested. The 
cellulose derivatives adsorbed 7 #g of IL-6 as determined by 
ELISA and attached only background numbers of HepG2 
cells (11%) in comparison with the respective cellulose de- 
rivatives not pretreated with Ib6, which attached 93-97% 
of the cells. These results provide evidence that the inhibi- 
tory effect  of Ib6 on the reaction between preS(21-47)-cellulose 
and cells expressing HBV receptors can be ascribed to a specific 
interaction between the preS(21-47) region of the HBV env 
protein and Ib6. 
To show that IL-6 reacted not only with preSl-specific 
ligands covalently linked to cellulose but also with HBV env 
proteins containing the preS1 sequence, a test for detecting 
HBsAg-Ib6 complexes was designed. Such complexes were 
detected in an ELISA utilizing polystyrene plates coated with 
antibodies to HBV env proteins  (anti- preS1 or anti-S) and 
biotinylated antibodies to IL-6 as a probe.  The association 
between Ib6 and HBV env proteins could be demonstrated 
only for HBsAg containing the preS1 sequence but not for 
HBsAg containing S protein or S protein and the preS2 se- 
quence only (Fig. 6). These results confirmed that the preS1 
region of the HBV env protein contained sites recognizing 
I1:6. Similar results were obtained by an ELISA in which 
plates coated with antibodies to S protein,  present in each 
of the envelope protein constituents of HBV, were used 
(Fig. 7). 
The association between ID6 and the preS1 region of the 
HBV env protein was confirmed by micro  filtration using 3 
x  10  2 kD cut-off ultrafiltration  membranes. II.-6 in the ab- 
sence of HBV env proteins  containing the preS1 sequence 
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Figure 7.  HBsAg-mediated  attachment  of II:6 to wells of polystyrene 
plates coated with polyclonal guinea  pig anti-HBs  (anti-S protein).  For 
further explanations,  see legend to Fig. 6. 
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Figure  8.  Effect  of preactivation  with  LPS  of human  PBMC  and 
promonocytic U937 cells on their attachment  to preS(21-47) cellulose. The 
attachment  of activated U937 cells was abrogated in the presence of poly- 
clonal rabbit anti-Ib6 (200 #g) (third row). The effect of anti-lb6 on at- 
tachment of LPS-activated PBMC was not tested. 
or in the presence of HBsAg containing S and M protein, 
or  S  protein  only,  was  quantitatively  recovered  in  the 
ultrafdtrate. However, IL-6 was partially recovered  in the reten- 
rate (33-87%, depending on the initial concentrations of the 
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Figure 9.  Release of IL-6 from distinct  cell lines by PI-PI,C or by ex- 
posure  to pH 4. Cells (106) were treated  for 1 h at 37~  with PI-PLC 
(100 #1;  1 U/ml in TS; second row),  mock treated  with "IS (first [front] 
row), or incubated in 10 mM citrate, 0A4 M NaC1, pH 4 (third row). IIr 
was determined  in supernatant  fluids after centrifugation  of the treated 
cells, and in lysed pelleted cells. The percentage of Ib6 recovered in the 
supernatant  fluids was calculated and plotted. The concentration  of IL-6 
in lysates of untreated  cells was in the range of 2.5-5.1 ng/ml, as calcu- 
lated from a calibration  curve relating ELLS& readings to concentration 
of an Ib6 standard. Similar results were obtained with Wish, SK-N-SH, 
and Con A-activated HUT 78 cells. 
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and recombinant L protein, respectively, were submitted to 
ultrafiltration.  The retention of I1-6 under the latter circum- 
stances was nearly completely suppressed (94%) when the 
peptide preS(12-47) was added at 50-M excess. The K~ for 
the reaction between I1-6 and the preS1 segment of the HBV 
env protein was calculated from the results of these experi- 
ments (K~  =  4.0  +_  0.94  x  109). 
Cell.associated  IL-6 Is Involved  in Recognition of  the preS(21-47) 
Segment of the HBV L Protein.  Purified I1-6 reacts with the 
preS1 region of the HBV env proteins,  and the preS(21-47) 
segment of the  sequence  is  involved  in  this  interaction. 
Blocking of this region of the HBV env protein by I1-6 pre- 
vented the interaction of HBV env proteins and of the pep- 
tide preS(21-47) with cell surface recognition sites. The fol- 
lowing results provide evidence that these recognition sites 
are located on cell surface-associated I1-6. 
Human PBMC do not produce I1.-6. LPS induces the syn- 
thesis of I1.6 in PBMC, which are the major source of IL-6 
produced by LPS-treated whole blood cultures (34, 35). The 
majority of human PBMC and promonocytic U937 cells did 
not attach to preS(21-47)-celhlose. However, after stimula- 
tion with LPS, these cells attached to this cellulose derivative 
(Fig. 8) and to HBs-cellulose (data not shown) but not to 
preS(12-32)-cellulose. The attachment of LPS-activated  U937 
cells to preS(21-47)-ceUulose  was abrogated by polyclonal an- 
tibodies  to I1.6. Polyclonal anti-IL-6 also inhibited the at- 
tachment to preS(21-47)-cellulose of other cell lines (U266, 
H9, FS-4, HepG2, COS-l, Namalwa, SK-N-SH, Cates 1B, 
and Con A-activated  MOLT-3) by 45-78%. 
Partially purified preparations of the HBV receptor were 
prepared by affinity chromatography  on preS(21-47)-cellulose 
(3). A lysate from 107 HepG2 cells was chromatographed on 
a minicolumn of preS(21-47)-ceUulose (8 mg) under condi- 
tions described before for the receptor purification. A major 
portion (78%  =  570 pg) of I1.6 originally present in the 
cell lysate was attached to the cellulose derivative and subse- 
quently eluted by 4 M MgC12. This indicates that I1.6 is 
selectively  removed from crude cell lysates in agreement with 
the observed binding between I1-6 and the preS(21-47) seg- 
ment of the HBV L protein. I1-6 was also removed from crude 
cell lysates by affinity chromatography on columns of im- 
mobilized anti-"receptor antibodies"  prepared as described 
before (3; data not shown). 
Unlike mature forms of some other growth factors (36), 
I1.6 is not cleaved  from integral membrane precursors. There- 
fore, it seemed possible that I1.6 involved in the interaction 
with the preS(21-47) segment of the preS1 sequence was 
peripherally associated with cell membranes. To confirm that 
this indeed was the case, cells were pretreated at pH 4, con- 
ditions known to release cell-associated lymphokines while 
preserving cell viability (17), and the attachment of the treated 
cells to preS(21-47)-cellulose as well as the release from the 
cells of I1-6 were measured.  Treatment at pH 4 abrogated 
the attachment to preS(21-47)-cellulose of the following cell 
lines tested: HepG2,  RPMI 8226, H9, FS-4, Wish, SK-N- 
SH,  Namalwa, Cates 1B, U266,  COS-l, Con A-activated 
HUT 78, and LPS-activated U937 cells. The release of II.-6 
at pH 4 from ceU lines expressing the highest levels of I1.6 
was assayed  by ELISA. Results shown in Fig. 9 indicate that 
most of the II.-6 was released from the cells at pH 4. These 
results indicate that cell-associated I1.6 is indeed involved in 
the interaction between cells and cellulose derivatives with 
immobilized preS1 ligands. Not surprisingly, partial release 
of I1.6 was also observed with mock-treated cells, in agree- 
ment with the observed shedding of HBV "receptors" into 
the extracellular environment (2). 
Initial attempts to characterize the receptor for HBV indi- 
cated that treatment of  distinct cell lines with PI-PLC resulted 
in decreased reactivity with the preS(21-47) binding site (Fig. 
2). Subsequent results indicated that the component recog- 
nizing the latter site was II-6. However, I1-6 is not attached 
to cell membranes by a PI anchor. To resolve this apparent 
discrepancy, I1-6 was measured in  supernatant  fluids after 
treating cells with PI-PLC. Most of the cell-associated I1-6 
was released after such treatment (Fig. 9). These results agree 
with the proposed role of I1.6 as a mediator of HBV attach- 
ment to cells, and suggest that I1-6 is functioning as an HBV 
receptor anchored to the cell surface  through another PI-PLC- 
releasable  component(s). Preliminary results suggest that this 
component(s)  is a proteoglycan. 
Discussion 
Although the liver is the major target organ for HBV, cells 
other than hepatocytes, including PBL, may become infected 
with the virus. In accordance with this, receptors for HBV 
were detected on cells of  both hepatic and extrahepatic origin 
(2). It was anticipated  that attempts to detect and charac- 
terize HBV receptors on several cell lines, rather than only 
on cells of hepatic origin, would provide clues concerning 
the nature of HBV receptors and an explanation for multiple 
target cells (organs) for HBV. These expectations lead to an 
experimental path finally revealing that I1.6 carries a binding 
site for HBV. The production of Ib6 by a variety of cells 
(37) may explain the miscellany of target ceils for HBV. Some 
of the ceUs (PBMC, promonocytic, and T cell lines) did not 
express Ib6 constitutively and did not react with the cell 
receptor binding site on HBV, but expressed both Ib6 and 
the binding site for HBV after activation.  This might ex- 
plain the reported replication of HBV in PBMC (9) and pe- 
ripheral T lymphocytes (8), and possibly contribute to ex- 
plaining the reactivation of latent hepatitis  virus infection 
of circulating lymphoid cells after activation with LPS (38). 
Aplastic anemia has occasionally  been diagnosed in patients 
infected with HBV, and it was observed that exposure of 
human bone marrow mononudear ceils to HBV resulted in 
suppression of in vitro growth of several hematopoietic pro- 
genitor ceils (39). The interaction between II.-6 and HBV, 
documented herein, might offer an explanation for the ob- 
served inhibition of proliferation  and differentiation  of he- 
matopoietic  colony-forming cells by HBV. 
The interaction between growth factors or growth factor 
receptors with viral envelope proteins  (10, 11,  14,  15), and 
467  Neurath et al. mimicking of cytokines or their receptors by virally encoded 
proteins (12,  16), provide new insights  into the replication 
of the corresponding viruses and explanations for their effects 
on the host immune system. The demonstration that HBV 
utilizes Ib6 as a target for attachment to cells suggests that 
this virus should be included in an apparently expanding family 
of viral pathogens capable of modulating  cell growth and 
differentiation. 
IL-6 involved in the interaction  between HBV and cells 
appeared to be associated with  the cell periphery through 
another component, attached to the cell membrane through 
a PI anchor. Preliminary  results suggest that this component(s) 
is a proteoglycan (own unpublished data). This observation 
appears to agree with the proposed role of proteoglycans as 
modulators of growth factor activities (40), although no ex- 
perimental evidence for the association of IL-6 with proteo- 
glycans has been reported so far. Some of the proteoglycans 
are linked to the cell membrane by a PI anchor (41), possibly 
explaining the release of II.,6- and HBV-binding activity from 
cells by PI-PLC. I1.-6 and proteoglycans may possibly play a 
dual role in attachment  of HBV to cells. 
The interaction between I1r  and the preS1 region of the 
HBV envelope appears  to be responsible for the primary in- 
teraction of HBV with cells. The precise details of cell-HBV 
interactions,  probably involving other cell membrane com- 
ponents (proteoglycans?),  and possibly also regions on the 
HBV env protein other than the preS(21-47) segment, leading 
to productive infection ofceUs, remain to be established. This 
task is complicated by the unavailability of a system for quan- 
titating  infectious  HBV.  The  location  of the  preS(21-47) 
binding  site on I1.-6 and its similarity to or distinctiveness 
from the domain involved in interaction with Ib6R also re- 
main  to be explored. 
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